for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bio-Rad Laboratories, Inc.

BIO

Latest Trade

601.68USD

Change

-1.29(-0.21%)

Volume

95,713

Today's Range

598.30

 - 

605.92

52 Week Range

425.43

 - 

689.00

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Bio Rad Laboratories Reports Q1 Non-GAAP Earnings Per Share Of $5.21

April 29 (Reuters) - Bio Rad Laboratories Inc <BIO.N>::BIO-RAD REPORTS FIRST-QUARTER 2021 FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $5.21.Q1 EARNINGS PER SHARE $32.38.Q1 SALES ROSE 27.1 PERCENT TO $726.8 MILLION.FOR FULL YEAR 2021 ANTICIPATES NON-GAAP CURRENCY-NEUTRAL REVENUE GROWTH OF APPROXIMATELY 5.5 TO 6.0 PERCENT.

Bio-Rad Reports Fourth-Quarter And Full-Year 2020 Financial Results

Feb 11 (Reuters) - Bio Rad Laboratories Inc <BIO.N>::BIO-RAD REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 FINANCIAL RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $4.01.Q4 EARNINGS PER SHARE $27.81.Q4 SALES $789.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $686.8 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $3.30 -- REFINITIV IBES DATA.FOR 2021, ANTICIPATES NON-GAAP CURRENCY-NEUTRAL REVENUE GROWTH OF ABOUT 4.5 TO 5.0%.SEES 2021 ESTIMATED NON-GAAP OPERATING MARGIN OF ABOUT 16.0% TO 16.5%.

Bio Rad Laboratories Initiated Restructuring Plan In Furtherance Of Co's Ongoing Program To Improve Operating Performance

Feb 4 (Reuters) - Bio Rad Laboratories Inc <BIO.N>::BIO RAD LABORATORIES - INITIATED RESTRUCTURING PLAN IN FURTHERANCE OF CO'S ONGOING PROGRAM TO IMPROVE OPERATING PERFORMANCE.BIO RAD LABORATORIES INC - RESTRUCTURING PLAN PRIMARILY IMPACTS OPERATIONS IN EUROPE, INCLUDES ELIMINATION OF CERTAIN POSITIONS.BIO RAD LABORATORIES INC - RESTRUCTURING PLAN IS EXPECTED TO ELIMINATE A TOTAL OF APPROXIMATELY 530 POSITIONS.BIO RAD LABORATORIES INC - RESTRUCTURING PLAN EXPECTS TO CREATE TOTAL OF APPROXIMATELY 325 NEW POSITIONS.BIO RAD LABORATORIES INC - ANTICIPATES RESTRUCTURING PLAN WILL BE IMPLEMENTED IN PHASES.BIO RAD LABORATORIES INC - ANTICIPATES RESTRUCTURING PLAN TO BE SUBSTANTIALLY COMPLETED BY END OF 2022.BIO RAD LABORATORIES INC - ESTIMATES IN RESTRUCTURING PLAN, CO WILL INCUR BETWEEN ABOUT $125 MILLION AND $130 MILLION IN TOTAL COST.BIO RAD LABORATORIES - EXPECTS TO RECORD BETWEEN ABOUT $80 MILLION TO $90 MILLION CHARGES RELATED TO RESTRUCTURING PLAN IN Q1 OF 2021.

Bio Rad Laboratories Sees FY Sales $2.75 Billion To $2.85 Billion

Bio Rad Laboratories Inc <BIO.N>::SEES FY SALES $2.75 BILLION TO $2.85 BILLION.EXPECTS FISCAL YEAR 2023 SALES TO BE BETWEEN $2.75 BILLION AND $2.85 BILLION.BIO RAD LABORATORIES - FOR FISCAL YEAR 2023, EXPECTS TO ACHIEVE NON-GAAP ADJUSTED EBITDA MARGIN OF 23 TO 24%.

Bio-Rad Reports Third-Quarter 2020 Financial Results

Oct 29 (Reuters) - Bio Rad Laboratories Inc <BIO.N>::BIO-RAD REPORTS THIRD-QUARTER 2020 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $3.00.Q3 EARNINGS PER SHARE $43.64.Q3 SALES $647.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $570.6 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $1.80 -- REFINITIV IBES DATA.BIO RAD LABORATORIES - CURRENTLY BELIEVES FULL-YEAR 2020 YOY CURRENCY-NEUTRAL SALES MAY BE UP 5.9 TO 6.3 PERCENT.

Bio Rad Laboratories Reports Q2 Earnings Per Share $32.15

July 30 (Reuters) - Bio Rad Laboratories Inc <BIO.N>::BIO-RAD REPORTS SECOND-QUARTER 2020 FINANCIAL RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $1.61.Q2 EARNINGS PER SHARE $32.15.Q2 SALES $536.9 MILLION VERSUS REFINITIV IBES ESTIMATE OF $517.1 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $1.22 -- REFINITIV IBES DATA.CURRENTLY BELIEVES THAT Q3 2020 YEAR-OVER-YEAR CURRENCY-NEUTRAL SALES MAY BE FLAT TO UP 5%.

Bio Rad Laboratories Estimates Q2 Currency-Neutral Sales To Decline By 5% To 10%

May 21 (Reuters) - Bio Rad Laboratories Inc <BIO.N>::BIO RAD LABORATORIES SAYS IT EXPECTS Q2 2020 YEAR-OVER-YEAR CURRENCY NEUTRAL SALES MAY DECLINE BY 5 TO 10 PERCENT - SEC FILING.

Bio-Rad Reports Q1 Non-GAAP Earnings Per Share $1.91

May 6 (Reuters) - Bio Rad Laboratories Inc <BIO.N>::BIO-RAD REPORTS FIRST-QUARTER 2020 FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $1.91.Q1 EARNINGS PER SHARE $22.72.Q1 SALES ROSE 3.2 PERCENT TO $571.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.57 -- REFINITIV IBES DATA.SEES Q2 SALES DOWN 10 TO 15 PERCENT.WITHDRAWING OUR PREVIOUSLY ISSUED ANNUAL GUIDANCE FOR THIS YEAR.

Bio-Rad Acquires Celsee Inc

April 9 (Reuters) - Bio Rad Laboratories Inc <BIO.N>::BIO-RAD ACQUIRES CELSEE, INC., A SINGLE-CELL ANALYSIS SOLUTIONS PROVIDER.BIO RAD LABORATORIES INC - TERMS OF ACQUISITION WERE NOT DISCLOSED.

Bio-Rad To Launch Serology Assay To Detect Coronavirus Antibodies

April 7 (Reuters) - Bio Rad Laboratories Inc <BIO.N>::BIO-RAD ANNOUNCES THE LAUNCH OF A SEROLOGY ASSAY TO DETECT CORONAVIRUS (COVID-19) ANTIBODIES.BIO RAD LABORATORIES INC - PLANS TO OFFER IMMUNOASSAY KIT GLOBALLY.BIO RAD LABORATORIES INC - IN UNITED STATES, CO INTENDS TO USE FDA'S EMERGENCY USE AUTHORIZATION PROCESS TO EXPEDITE U.S. AVAILABILITY.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up